237 related articles for article (PubMed ID: 10477211)
1. Is glycation of low density lipoproteins in patients with Type 2 diabetes mellitus a LDL pre-oxidative condition?
Moro E; Alessandrini P; Zambon C; Pianetti S; Pais M; Cazzolato G; Bon GB
Diabet Med; 1999 Aug; 16(8):663-9. PubMed ID: 10477211
[TBL] [Abstract][Full Text] [Related]
2. Effects of Vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to oxidation and on protein glycation in NIDDM.
Reaven PD; Herold DA; Barnett J; Edelman S
Diabetes Care; 1995 Jun; 18(6):807-16. PubMed ID: 7555507
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of serum biomarkers in nutritional disorders: glycated apolipoprotein B, fasting serum glucose, fructosamine, stable and labile glycated hemoglobin in diabetic and non-diabetic subjects.
De Michele G; Correale M; De Michele O; Guerra V; Mazzarelli R; Misciagna G
Immunopharmacol Immunotoxicol; 2008; 30(4):925-36. PubMed ID: 18720163
[TBL] [Abstract][Full Text] [Related]
4. Electronegative low density lipoprotein subform (LDL-) is increased in type 2 (non-insulin-dependent) microalbuminuric diabetic patients and is closely associated with LDL susceptibility to oxidation.
Moro E; Zambon C; Pianetti S; Cazzolato G; Pais M; Bittolo Bon G
Acta Diabetol; 1998 Oct; 35(3):161-4. PubMed ID: 9840454
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility of low- and high-density lipoproteins from diabetic subjects to in vitro oxidative modification.
Julier K; Mackness MI; Dean JD; Durrington PN
Diabet Med; 1999 May; 16(5):415-23. PubMed ID: 10342342
[TBL] [Abstract][Full Text] [Related]
6. Effect of glycemic optimization on electronegative low-density lipoprotein in diabetes: relation to nonenzymatic glycosylation and oxidative modification.
Sánchez-Quesada JL; Pérez A; Caixàs A; Rigla M; Payés A; Benítez S; Ordóñez-Llanos J
J Clin Endocrinol Metab; 2001 Jul; 86(7):3243-9. PubMed ID: 11443196
[TBL] [Abstract][Full Text] [Related]
7. Postprandial low-density lipoproteins in type 2 diabetes are oxidized more extensively than fasting diabetes and control samples.
Diwadkar VA; Anderson JW; Bridges SR; Gowri MS; Oelgten PR
Proc Soc Exp Biol Med; 1999 Nov; 222(2):178-84. PubMed ID: 10564543
[TBL] [Abstract][Full Text] [Related]
8. The transport of vitamin E in plasma and its correlation to plasma lipoproteins in non-insulin-dependent diabetes mellitus.
Kökoğlu E; Ulakoğlu E
Diabetes Res Clin Pract; 1991 Dec; 14(3):175-81. PubMed ID: 1778110
[TBL] [Abstract][Full Text] [Related]
9. Impact of concentrations of glycated hemoglobin, alpha-tocopherol, copper, and manganese on oxidation of low-density lipoproteins in patients with type I diabetes, type II diabetes and control subjects.
Leonhardt W; Hanefeld M; Müller G; Hora C; Meissner D; Lattke P; Paetzold A; Jaross W; Schroeder HE
Clin Chim Acta; 1996 Oct; 254(2):173-86. PubMed ID: 8896905
[TBL] [Abstract][Full Text] [Related]
10. The expression of apolipoprotein B epitopes is normal in LDL of diabetic and end-stage renal disease patients.
Braschi S; Geoffrion M; Nguyen A; Gaudreau Y; Milne RW
Diabetologia; 2006 Jun; 49(6):1394-401. PubMed ID: 16586068
[TBL] [Abstract][Full Text] [Related]
11. Increased glycation and oxidative damage to apolipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin.
Rabbani N; Chittari MV; Bodmer CW; Zehnder D; Ceriello A; Thornalley PJ
Diabetes; 2010 Apr; 59(4):1038-45. PubMed ID: 20068133
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein abnormalities in well-treated type II diabetic patients.
Manzato E; Zambon A; Lapolla A; Zambon S; Braghetto L; Crepaldi G; Fedele D
Diabetes Care; 1993 Feb; 16(2):469-75. PubMed ID: 8432219
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein composition in NIDDM: effects of dietary oleic acid on the composition, oxidisability and function of low and high density lipoproteins.
Dimitriadis E; Griffin M; Collins P; Johnson A; Owens D; Tomkin GH
Diabetologia; 1996 Jun; 39(6):667-76. PubMed ID: 8781762
[TBL] [Abstract][Full Text] [Related]
14. Glycated low density lipoprotein catabolism is increased in rabbits with alloxan-induced diabetes mellitus.
Kortlandt W; Benschop C; van Rijn HJ; Erkelens DW
Diabetologia; 1992 Mar; 35(3):202-7. PubMed ID: 1563579
[TBL] [Abstract][Full Text] [Related]
15. Association between plasma oxidized low-density lipoprotein and diabetic nephropathy.
Ujihara N; Sakka Y; Takeda M; Hirayama M; Ishii A; Tomonaga O; Babazono T; Takahashi C; Yamashita K; Iwamoto Y
Diabetes Res Clin Pract; 2002 Nov; 58(2):109-14. PubMed ID: 12213352
[TBL] [Abstract][Full Text] [Related]
16. Serum glycated lipoproteins in type II diabetic patients with and without complications.
Yeğin A; Ozben T
Ann Clin Biochem; 1995 Sep; 32 ( Pt 5)():459-63. PubMed ID: 8830620
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol.
Fonseca L; Paredes S; Ramos H; Oliveira JC; Palma I
Lipids Health Dis; 2020 Jun; 19(1):127. PubMed ID: 32505210
[TBL] [Abstract][Full Text] [Related]
18. Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes.
Tsuzura S; Ikeda Y; Suehiro T; Ota K; Osaki F; Arii K; Kumon Y; Hashimoto K
Metabolism; 2004 Mar; 53(3):297-302. PubMed ID: 15015140
[TBL] [Abstract][Full Text] [Related]
19. Increased plasma glycated low-density lipoprotein concentrations in diabetes: a marker of atherogenic risk.
Cohen MP; Jin Y; Lautenslager GT
Diabetes Technol Ther; 2004 Jun; 6(3):348-56. PubMed ID: 15198838
[TBL] [Abstract][Full Text] [Related]
20. E-selectin plasma concentration is influenced by glycaemic control in NIDDM patients: possible role of oxidative stress.
Cominacini L; Fratta Pasini A; Garbin U; Campagnola M; Davoli A; Rigoni A; Zenti MG; Pastorino AM; Lo Cascio V
Diabetologia; 1997 May; 40(5):584-9. PubMed ID: 9165228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
